

Efficacy of remibrutinib in patients with CSU by demographics and baseline characteristics: Pooled analysis from REMIX-1/-2 studies

S. Saini, A. Fukunaga, B. Yang, S. Haemmerle, El-D. Martzloff, C-E. Ortmann, K. Lheritier, V. Jain

Please click [HERE](#) to subscribe to news alerts of the Novartis Urticaria Knowledge Center and to receive an email notification once the publication is available

Or use this [LINK](#) to access the publication once it has been presented at the congress

EADV 2025, European Academy of Dermatology and Venereology. (EADV), 17–20 September 2025